文献速递浆细胞疾病造血干细胞移植与细胞治疗

新诊断多发性骨髓瘤自体干细胞移植前后沙利度胺治疗(HOVON-50):3期随机对照试验的长期结果

Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
PubMed 文献 · Lancet Haematol · 2018-01-01

HOVON-50 3期随机对照试验在44家荷兰和比利时医院纳入536例新诊断多发性骨髓瘤患者,比较含沙利度胺方案与含长春新碱方案在诱导和维持治疗中的长期疗效。中位随访129个月时,沙利度胺组无事件生存期显著优于对照组(多因素分析HR 0.62,95%CI 0.50-0.77;p<0.0001)。

要点

  • 中位随访129个月,沙利度胺组无事件生存期显著优于对照组(HR 0.62,95%CI 0.50-0.77;p<0.0001)。
  • 沙利度胺组155例中65例(42%)因毒性停止维持治疗,其中神经病变49例(75%)。
  • 两组第二原发恶性肿瘤频率相似,对照组17例患者发生23例次,沙利度胺组24例患者发生29例次。

核心结论

  • 沙利度胺为基础的治疗对于适合自体干细胞移植且所在国家无法获得蛋白酶体抑制剂或来那度胺的多发性骨髓瘤患者可能是一种治疗选择。
  • 作者认为,仔细随访和及时调整剂量对于预防沙利度胺诱导的神经毒性很重要。

研究设计与样本

  • 开放标签、3期随机对照试验,从44家荷兰和比利时医院招募新诊断多发性骨髓瘤患者。
  • 纳入Durie-Salmon II期或III期、年龄18-65岁的患者,按1:1随机分配至对照组或沙利度胺组,按中心和治疗政策(一程或两程大剂量美法仑和自体干细胞移植)分层。
  • 共入组556例患者,其中536例(96%)可评估并随机分配(对照组268例[50%],沙利度胺组268例[50%]),这536例患者评估主要终点EFSc。
  • 对照组诱导方案:长春新碱0.4 mg静脉快速输注第1-4天,多柔比星9 mg/m2静脉快速输注第1-4天,地塞米松40 mg口服第1-4天、第9-12天和第17-20天,每28天一个周期,共3个周期;沙利度胺组以沙利度胺200-400 mg口服第1-28天替代长春新碱。
  • 干细胞采集后,患者接受一程或两程美法仑200 mg/m2静脉输注联合自体干细胞移植;至少达到部分缓解的患者在大剂量美法仑后2-3个月开始维持治疗,对照组接受干扰素α 3×10^6国际单位皮下注射每周三次,沙利度胺组接受沙利度胺50 mg口服每日一次,维持治疗至复发、进展或不良事件发生。

主要发现

  • 2001年11月27日至2005年5月31日入组556例患者,其中536例(96%)可评估并随机分配(对照组268例[50%],沙利度胺组268例[50%])。
  • 中位随访延长至129个月(IQR 123-136)时,沙利度胺组EFSc显著长于对照组(多因素分析HR 0.62,95%CI 0.50-0.77;p<0.0001)。
  • 沙利度胺组155例患者中65例(42%)因毒性停止沙利度胺维持治疗:神经病变49例(75%),皮肤反应4例(6%),乏力2例(3%),其他症状(如腹痛、胰腺炎和呼吸困难)10例(15%)。
  • 对照组90例患者中24例(27%)在干扰素α维持治疗期间因毒性停止方案治疗:精神副作用5例(21%),流感样症状5例(21%),血液学毒性(血小板减少和白细胞减少)4例(17%),皮肤反应3例(13%),其他症状(如感染、心肌病和头痛)7例(29%)。
  • 两组第二原发恶性肿瘤频率相似:对照组17例患者发生23例第二原发恶性肿瘤,沙利度胺组24例患者发生29例第二原发恶性肿瘤;对照组治疗相关死亡19例,沙利度胺组治疗相关死亡16例。

临床怎么用

  • 作者认为,沙利度胺为基础的治疗对于适合自体干细胞移植且所在国家无法获得蛋白酶体抑制剂或来那度胺的多发性骨髓瘤患者可能是一种治疗选择。
  • 作者认为,仔细随访和及时调整剂量对于预防沙利度胺诱导的神经毒性很重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients with recently diagnosed multiple myeloma, the HOVON-50 phase 3 trial showed improved event-free survival for thalidomide-containing induction and maintenance regimens (in conjunction with high-dose melphalan and autologous stem cell transplantation [auto-SCT]) after a median of 52 months of follow-up, by comparison with regimens containing classical cytotoxic drugs. In this follow-up analysis, we aimed to determine the long-term effects of thalidomide in induction and maintenance therapy in multiple myeloma. METHODS: In this open-label, phase 3 randomised controlled trial, patients with recently diagnosed multiple myeloma were recruited from 44 Dutch and Belgian hospitals. Participants had been diagnosed with multiple myeloma of Durie-Salmon stage II or III and were aged 18-65 years. Patients were randomly assigned (1:1) either to receive three 28-day cycles of vincristine (0·4 mg, intravenous rapid infusion on days 1-4), doxorubicin (9 mg/m2, intravenous rapid infusion on days 1-4) and dexamethasone (40 mg, orally on days 1-4, 9-12, and 17-20; control group); or to receive the same regimen, but with thalidomide (200-400 mg, orally on days 1-28) instead of vincristine (thalidomide group). No masking after assignment to intervention was used. Patients were randomly assigned to groups, stratified by centre and treatment policy (one vs two courses of high-dose melphalan and auto-SCT). After stem cell harvest, patients received one or two courses of 200 mg/m2 melphalan intravenously with auto-SCT. Patients with at least a partial response to high-dose melphalan and auto-SCT were eligible for maintenance therapy, starting 2-3 months after high-dose melphalan. Patients in the control group received maintenance therapy with interferon alfa (3 × 106 international units, subcutaneously, three times weekly). Patients in the thalidomide group received thalidomide as maintenance therapy (50 mg, orally, daily). Maintenance therapy was given until relapse, progression, or the occurrence of adverse events. The primary endpoint of the study was event-free survival (EFSc; censored at allogeneic stem cell transplantation), analysed by intention to treat. The study is closed for enrolment and this Article represents the final analysis. This trial was registered with the Netherlands Trial Register, number NTR238. FINDINGS: Between Nov 27, 2001 and May 31, 2005, 556 patients were enrolled in the study, of whom 536 (96%) were eligible for evaluation and were randomly allocated (268 [50%] to the control group and 268 [50%] to the thalidomide group). These 536 patients were assessed for the primary endpoint of EFSc. At an extended median follow-up of 129 months (IQR 123-136), EFSc was significantly longer in the thalidomide group compared with the control group (multivariate analysis hazard ratio [HR] 0·62, 95% CI 0·50-0·77; p<0·0001). Thalidomide maintenance was stopped because of toxicity in 65 (42%) of 155 patients in the thalidomide group (neuropathy in 49 [75%] patients, skin reactions in four [6%] patients, fatigue in two [3%] patients, and as other symptoms [such as abdominal pain, pancreatitis, and dyspnoea] in ten [15%] patients). 24 (27%) of 90 patients in the control group discontinued protocol treatment during maintenance therapy with interferon alfa because of toxicity (five [21%] patients with psychiatric side-effects, five [21%] patients with flu-like symptoms, four [17%] patients with haematological toxicity [thrombocytopenia and leucocytopenia], three [13%] patients with skin reactions, and seven [29%] patients with other symptoms [such as infections, cardiomyopathy, and headache]). The frequency of second primary malignancies was similar in both groups. There were 23 second primary malignancies in 17 patients in the control group and 29 second primary malignancies in 24 patients in the thalidomide group. There were 19 treatment-related deaths in the control group, and 16 treatment-related deaths in the thalidomide group. INTERPRETATION: Our data indicate that thalidomide-based treatment could be a treatment option for patients with multiple myeloma who are eligible for auto-SCT who live in countries without access to proteasome inhibitors or lenalidomide. However, careful follow-up and timely dose adjustments are important to prevent the development of thalidomide-induced neurotoxicity. FUNDING: The Dutch Cancer Foundation.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. van de Donk NW, van der Holt B, Minnema MC, et al. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol. 2018. PMID: 30290905. doi:10.1016/S2352-3026(18)30149-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。